Literature DB >> 26357000

IL-31 and IL-33 circulating levels in allergic contact dermatitis.

F Guarneri1, P L Minciullo2, C Mannucci3, F Calapai3, S Saitta4, S P Cannavò1, S Gangemi5.   

Abstract

Enhanced IL-31 expression in skin biopsies is present in allergic contact dermatitis (ACD). IL-33 expression is induced in keratinocytes and in skin of ACD patients. This overexpression is present in both allergic and irritant conditions. The aim of this work was to test the systemic involvement of IL-31 and IL-33 in ACD. IL-31 levels were significantly higher in patients than in controls. IL-33 serum levels, on the contrary, were similar in patients and controls. This work shows a possible systemic involvement of IL-31 and the absence of a systemic involvement of IL-33 in ACD. IL-31 levels do not seem related to the allergen involved, and did not change on the strength of the allergen involved. More likely, IL-31 levels are related to the itch. IL-33, instead, is secreted from damaged or inflamed tissue and might function as an early warning system at the site of skin damage. In the future, IL-31 could be a possible therapeutic target of all pruritic skin diseases resistant to conventional therapies.

Entities:  

Keywords:  Allergic contact dermatitis; cytokines; interleukin-31; interleukin-33; pruritic skin disease; pruritus

Mesh:

Substances:

Year:  2015        PMID: 26357000

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  11 in total

Review 1.  Application of proteomics in the elucidation of chemical-mediated allergic contact dermatitis.

Authors:  Tessa Höper; Franz Mussotter; Andrea Haase; Andreas Luch; Tewes Tralau
Journal:  Toxicol Res (Camb)       Date:  2017-06-13       Impact factor: 3.524

Review 2.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 3.  IL-31: State of the Art for an Inflammation-Oriented Interleukin.

Authors:  Francesco Borgia; Paolo Custurone; Federica Li Pomi; Raffaele Cordiano; Clara Alessandrello; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 4.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

Review 5.  Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?

Authors:  Martin Voss; Johanna Kotrba; Evelyn Gaffal; Konstantinos Katsoulis-Dimitriou; Anne Dudeck
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

6.  IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.

Authors:  Giuseppe Murdaca; Monica Greco; Alessandro Tonacci; Simone Negrini; Matteo Borro; Francesco Puppo; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

Review 7.  Interleukin-31 as a Clinical Target for Pruritus Treatment.

Authors:  Kenji Kabashima; Hiroyuki Irie
Journal:  Front Med (Lausanne)       Date:  2021-02-12

Review 8.  IL-33/IL-31 Axis: A Potential Inflammatory Pathway.

Authors:  Eleonora Di Salvo; Elvira Ventura-Spagnolo; Marco Casciaro; Michele Navarra; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2018-03-11       Impact factor: 4.711

9.  IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch.

Authors:  Maria Abreu; Marta Miranda; Mafalda Castro; Iolanda Fernandes; Renata Cabral; Ana Helena Santos; Sónia Fonseca; João Rodrigues; Magdalena Leander; Catarina Lau; Inês Freitas; Susana Coimbra; Alice Santos-Silva; Margarida Lima
Journal:  Adv Hematol       Date:  2021-07-20

10.  The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?

Authors:  Karolina Świerczyńska; Piotr K Krajewski; Danuta Nowicka-Suszko; Rafał Białynicki-Birula; Magdalena Krajewska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2022-03-07       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.